GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 3,639 Shares

Posted by Shane Hupp on Jun 11th, 2026

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $53.77, for a total transaction of $195,669.03. Following the completion of the transaction, the chief executive officer owned 96,123 shares of the company’s stock, valued at approximately $5,168,533.71. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68.
On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61.
On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total transaction of $1,319,347.20.

GeneDx Price Performance

NASDAQ:WGS traded up $6.67 during midday trading on Thursday, hitting $60.99. 1,870,644 shares of the stock were exchanged, compared to its average volume of 1,047,962. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -22.76 and a beta of 1.96. The business has a 50-day moving average price of $55.13 and a two-hundred day moving average price of $91.01. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS – Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period in the previous year, the firm earned ($0.23) EPS. Sell-side analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current year.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

Negative Sentiment: Multiple law firms announced or reminded investors about a class action lawsuit against GeneDx, with deadlines for lead plaintiff participation centered on August 3, 2026. WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
Negative Sentiment: The lawsuits allege GeneDx and executives made false or misleading statements about acquisition performance, reimbursement rates, and margin compression, and that investors were harmed after a sharp stock decline tied to the Q1 2026 earnings report. GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman
Neutral Sentiment: One potentially supportive signal came from filings showing Casdin Capital added to its GeneDx position, which may indicate some institutional confidence despite the legal overhang. Casdin Capital, Llc Acquires 150,000 Shares of GeneDx (NASDAQ:WGS) Stock

Analysts Set New Price Targets

WGS has been the topic of a number of research reports. Guggenheim dropped their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Weiss Ratings lowered shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Finally, Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GeneDx has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Read Our Latest Report on GeneDx

Institutional Trading of GeneDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in WGS. Jones Financial Companies Lllp lifted its stake in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in GeneDx during the fourth quarter valued at approximately $27,000. Fifth Third Bancorp acquired a new stake in GeneDx during the first quarter valued at approximately $31,000. Quarry LP lifted its stake in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. Finally, Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the 4th quarter valued at approximately $33,000. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

(Get Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.